Transoral Robotic Surgery for Recurrent Tumors of the Upper Aerodigestive Tract (RECUT): An International Cohort Study

Author:

Hardman John C1ORCID,Holsinger F Chris2ORCID,Brady Grainne C3ORCID,Beharry Avinash4ORCID,Bonifer Alec T5ORCID,D’Andréa Gregoire6,Dabas Surender K7,de Almeida John R8ORCID,Duvvuri Umamaheswar9ORCID,Floros Peter10ORCID,Ghanem Tamer A5ORCID,Gorphe Philippe6ORCID,Gross Neil D11ORCID,Hamilton David12ORCID,Kurukulasuriya Chareeni9ORCID,Larsen Mikkel Hjordt Holm13ORCID,Lin Daniel J12ORCID,Magnuson J Scott10ORCID,Meulemans Jeroen14ORCID,Miles Brett A15ORCID,Moore Eric J16ORCID,Pantvaidya Gouri17ORCID,Roof Scott18ORCID,Rubek Niclas13ORCID,Simon Christian4,Subash Anand7ORCID,Topf Michael C19ORCID,Van Abel Kathryn M16ORCID,Vander Poorten Vincent14ORCID,Walgama Evan S11ORCID,Greenlay Emily20ORCID,Potts Laura20ORCID,Balaji Arun21ORCID,Starmer Heather M2,Stephen Sarah12,Roe Justin3ORCID,Harrington Kevin1ORCID,Paleri Vinidh1ORCID

Affiliation:

1. Head and Neck Unit, The Royal Marsden Hospital , London, UK

2. Department of Otolaryngology—H&N Surgery, Stanford University Medical Center , Palo Alto, CA, USA

3. Department of Speech, Voice and Swallowing, The Royal Marsden Hospital , London, UK

4. Department of Otolaryngology—H&N Surgery, Lausanne University Hospital , Lausanne, Switzerland

5. Department of Otolaryngology—H&N Surgery, Henry Ford Hospital , Detroit, MI, USA

6. Head and Neck Oncology Department, Institute Gustave Roussy , Paris, France

7. Department of Surgical Oncology and Robotic Surgery, BL Kapur Memorial Hospital , New Delhi, India

8. Department of Otolaryngology—H&N Surgery, University Health Network , Toronto, ON, Canada

9. Department of Otolaryngology, Eye & Ear Institute, University of Pittsburgh , Pittsburgh, PA, USA

10. Department of Otolaryngology—H&N Surgery, Florida Hospital Group , Celebration, FL, USA

11. Department of H&N Surgery, MD Anderson Cancer Center , Houston, TX, USA

12. Department of Otolaryngology—H&N Surgery, The Newcastle upon Tyne Hospitals , Newcastle, UK

13. Department of Head and Neck Surgery, Copenhagen University Hospital , Copenhagen, Denmark

14. Otorhinolaryngology—Head & Neck Surgery, University Hospitals Leuven, and Department of Oncology, Section Head and Neck Oncology, KU Leuven , Leuven, Belgium

15. Department of Otolaryngology Head and Neck Surgery, Northwell Health System , New York, NY, USA

16. Department of Otolaryngology—H&N Surgery, Mayo Clinic , Rochester, MN, USA

17. Department of H&N Surgery, Tata Memorial Hospital , Mumbai, India

18. Department of Otolaryngology, Mount Sinai Hospital , New York City, NY, USA

19. Department of Otolaryngology—H&N Surgery, Vanderbilt University Medical Center , Nashville, TN, USA

20. Clinical Trials Unit, The Royal Marsden Hospital , London, UK

21. Department of H&N Surgery, Tata Memorial Hospital, Homi Bhabha National Institute , Mumbai, India

Abstract

Abstract Background Transoral robotic surgery (TORS) is an emerging minimally invasive surgical treatment for residual, recurrent, and new primary head and neck cancers in previously irradiated fields, with limited evidence for its oncological effectiveness. Methods A retrospective observational cohort study of consecutive cases performed in 16 high-volume international centers before August 2018 was conducted (registered at clinicaltrials.gov [NCT04673929] as the RECUT study). Overall survival (OS), disease-free survival, disease-specific survivals (DSS), and local control (LC) were calculated using Kaplan-Meier estimates, with subgroups compared using log-rank tests and Cox proportional hazards modeling for multivariable analysis. Maximally selected rank statistics determined the cut point for closest surgical resection margin based on LC. Results Data for 278 eligible patients were analyzed, with median follow-up of 38.5 months. Two-year and 5-year outcomes were 69.0% and 62.2% for LC, 71.8% and 49.8% for OS, 47.2% and 35.7% for disease-free survival, and 78.7% and 59.1% for disease-specific survivals. The most discriminating margin cut point was 1.0 mm; the 2-year LC was 80.9% above and 54.2% below or equal to 1.0 mm. Increasing age, current smoking, primary tumor classification, and narrow surgical margins (≤1.0 mm) were statistically significantly associated with lower OS. Hemorrhage with return to theater was seen in 8.1% (n = 22 of 272), and 30-day mortality was 1.8% (n = 5 of 272). At 1 year, 10.8% (n = 21 of 195) used tracheostomies, 33.8% (n = 66 of 195) used gastrostomies, and 66.3% (n = 53 of 80) had maintained or improved normalcy of diet scores. Conclusions Data from international centers show TORS to treat head and neck cancers in previously irradiated fields yields favorable outcomes for LC and survival. Where feasible, TORS should be considered the preferred surgical treatment in the salvage setting.

Funder

Oracle Cancer Trust

International Centre for Recurrent Head & Neck Cancer

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3